$5.37
+0.18
(+3.47%)▲
Live
5.32%
Downside
Day's Volatility :6.71%
Upside
1.47%
66.48%
Downside
52 Weeks Volatility :67.86%
Upside
4.11%
Period | Lensar Inc | Index (Russel 2000) |
---|---|---|
3 Months | 65.74% | 0.0% |
6 Months | 39.84% | 0.0% |
1 Year | 61.26% | 0.0% |
3 Years | -30.53% | -20.2% |
Market Capitalization | 59.2M |
Book Value | $2.79 |
Earnings Per Share (EPS) | -1.1 |
Wall Street Target Price | 8.0 |
Profit Margin | -27.57% |
Operating Margin TTM | -26.92% |
Return On Assets TTM | -12.79% |
Return On Equity TTM | -28.86% |
Revenue TTM | 44.5M |
Revenue Per Share TTM | 4.0 |
Quarterly Revenue Growth YOY | 28.299999999999997% |
Gross Profit TTM | 20.0M |
EBITDA | -8.5M |
Diluted Eps TTM | -1.1 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.01 |
EPS Estimate Next Year | -0.84 |
EPS Estimate Current Quarter | -0.28 |
EPS Estimate Next Quarter | -0.26 |
What analysts predicted
Upside of 48.98%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 30.5M | - |
Net Income | -16.7M | - |
Net Profit Margin | -54.76% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 26.4M | ↓ 13.58% |
Net Income | -21.2M | ↑ 26.72% |
Net Profit Margin | -80.29% | ↓ 25.53% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 34.5M | ↑ 30.62% |
Net Income | -19.7M | ↓ 7.22% |
Net Profit Margin | -57.03% | ↑ 23.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 35.4M | ↑ 2.61% |
Net Income | -19.7M | ↓ 0.01% |
Net Profit Margin | -55.58% | ↑ 1.45% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 42.2M | ↑ 19.25% |
Net Income | -14.4M | ↓ 26.81% |
Net Profit Margin | -34.11% | ↑ 21.47% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 10.2M | ↑ 32.06% |
Net Income | -3.2M | ↓ 18.16% |
Net Profit Margin | -31.19% | ↑ 19.13% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.3M | ↓ 19.35% |
Net Income | -4.5M | ↑ 39.74% |
Net Profit Margin | -54.04% | ↓ 22.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.0M | ↑ 45.56% |
Net Income | -8.8M | ↑ 96.3% |
Net Profit Margin | -72.87% | ↓ 18.83% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.8M | ↓ 18.46% |
Net Income | 2.6M | ↓ 129.34% |
Net Profit Margin | 26.22% | ↑ 99.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 12.1M | ↑ 23.58% |
Net Income | -3.9M | ↓ 252.88% |
Net Profit Margin | -32.43% | ↓ 58.65% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.6M | ↓ 12.53% |
Net Income | -2.2M | ↓ 45.06% |
Net Profit Margin | -20.37% | ↑ 12.06% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 34.5M | - |
Total Liabilities | 65.1M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 79.1M | ↑ 129.09% |
Total Liabilities | 11.9M | ↓ 81.7% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 66.5M | ↓ 15.99% |
Total Liabilities | 11.6M | ↓ 2.72% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 55.8M | ↓ 15.98% |
Total Liabilities | 13.9M | ↑ 19.63% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 69.6M | ↑ 24.61% |
Total Liabilities | 22.4M | ↑ 61.68% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 55.8M | ↑ 1.9% |
Total Liabilities | 13.9M | ↑ 13.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 52.0M | ↓ 6.95% |
Total Liabilities | 12.5M | ↓ 9.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 71.2M | ↑ 37.02% |
Total Liabilities | 38.5M | ↑ 207.48% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 70.9M | ↓ 0.48% |
Total Liabilities | 34.5M | ↓ 10.48% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 69.6M | ↓ 1.79% |
Total Liabilities | 22.4M | ↓ 34.99% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 66.1M | ↓ 4.96% |
Total Liabilities | 20.6M | ↓ 8.29% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.9M | - |
Investing Cash Flow | -3.9M | - |
Financing Cash Flow | 7.0M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.6M | ↑ 567.85% |
Investing Cash Flow | -2.1M | ↓ 46.33% |
Financing Cash Flow | 15.9M | ↑ 129.32% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.8M | ↑ 9.55% |
Investing Cash Flow | -326.0K | ↓ 84.39% |
Financing Cash Flow | 50.0M | ↑ 213.51% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -9.0M | ↓ 34.96% |
Investing Cash Flow | -354.0K | ↑ 8.59% |
Financing Cash Flow | 361.0K | ↓ 99.28% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.9M | ↑ 65.64% |
Investing Cash Flow | -115.0K | ↓ 67.51% |
Financing Cash Flow | -2.0M | ↓ 651.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.8M | ↑ 1.21% |
Investing Cash Flow | -57.0K | ↑ 2750.0% |
Financing Cash Flow | 196.0K | ↓ 116.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.7M | ↑ 40.73% |
Investing Cash Flow | -8.0K | ↓ 85.96% |
Financing Cash Flow | 19.8M | ↑ 10012.76% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.1M | ↓ 67.98% |
Investing Cash Flow | -181.0K | ↑ 2162.5% |
Financing Cash Flow | 19.8M | ↑ 0.0% |
Sell
Neutral
Buy
Lensar Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Lensar Inc | 22.32% | 39.84% | 61.26% | -30.53% | -40.33% |
![]() Stryker Corporation | -3.84% | 5.16% | 12.86% | 24.25% | 52.69% |
![]() Boston Scientific Corp. | -3.68% | 21.48% | 41.72% | 68.89% | 76.47% |
![]() Edwards Lifesciences Corp. | -34.8% | -18.49% | -34.85% | -45.17% | -15.86% |
![]() Abbott Laboratories | 1.03% | -5.4% | -7.12% | -11.35% | 20.75% |
![]() Medtronic Plc | -1.99% | -9.34% | -13.21% | -38.74% | -23.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Lensar Inc | NA | NA | NA | -1.01 | -0.29 | -0.13 | NA | 2.79 |
![]() Stryker Corporation | 38.91 | 38.91 | 2.92 | 11.95 | 0.19 | 0.07 | 0.01 | 50.33 |
![]() Boston Scientific Corp. | 63.22 | 63.22 | 1.8 | 2.37 | 0.09 | 0.05 | NA | 13.16 |
![]() Edwards Lifesciences Corp. | 36.4 | 36.4 | 5.19 | 2.76 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 33.84 | 33.84 | 5.99 | 4.66 | 0.15 | 0.06 | 0.02 | 22.31 |
![]() Medtronic Plc | 28.97 | 28.97 | 1.52 | 5.2 | 0.07 | 0.04 | 0.04 | 38.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Lensar Inc | Buy | $59.2M | -40.33% | NA | -27.57% |
![]() Stryker Corporation | Buy | $129.7B | 52.69% | 38.91 | 16.03% |
![]() Boston Scientific Corp. | Buy | $114.3B | 76.47% | 63.22 | 12.05% |
![]() Edwards Lifesciences Corp. | Buy | $52.4B | -15.86% | 36.4 | 23.74% |
![]() Abbott Laboratories | Buy | $186.6B | 20.75% | 33.84 | 13.65% |
![]() Medtronic Plc | Buy | $102.5B | -23.49% | 28.97 | 11.36% |
Insights on Lensar Inc
Revenue is down for the last 2 quarters, 12.10M → 10.58M (in $), with an average decrease of 12.5% per quarter
Netprofit is up for the last 2 quarters, -3.92M → -2.15M (in $), with an average increase of 82.0% per quarter
In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 99.4%
Park West Asset Management LLC
Dimensional Fund Advisors, Inc.
Vanguard Group Inc
Brandes Investment Partners & Co
Renaissance Technologies Corp
DCF Advisers, LLC
lensar® is the leader in next-generation femtosecond laser technology for refractive cataract surgery. the lensar laser system offers cataract surgeons precision and accuracy, while optimizing overall visual outcomes. the proprietary augmented reality™, lensar’s reconstructed 3-d imaging, measurement, and guidance system, provides high-resolution ocular images in a single scan. this technology facilitates precise surgical incisions and treatment for ultimate accuracy and reliable outcomes, all in a single procedure room. the lensar laser system is the only femtosecond cataract laser built specifically for refractive cataract surgery. because it was designed from the ground up, every aspect of the laser has been purposefully designed to meet the needs of cataract surgeons. lensar, inc. is committed to revolutionizing refractive eye surgery. our success depends on talented and motivated individuals who share our passion for making a difference in patients’ lives. we are a young and vibra
Organization | Lensar Inc |
Employees | 130 |
CEO | Mr. Nicholas T. Curtis |
Industry | Health Technology |
A Spac I Acquisition Corp
$5.37
+3.47%
Keyarch Acquisition Corp
$5.37
+3.47%
Connexa Sports Technologies Inc
$5.37
+3.47%
Us Value Etf
$5.37
+3.47%
First Wave Biopharma Inc
$5.37
+3.47%
Global X Msci Next Emerging
$5.37
+3.47%
Fat Projects Acquisition Corp
$5.37
+3.47%
Capital Link Global Fintech
$5.37
+3.47%
Applied Uv Inc
$5.37
+3.47%